Immunic CMO on Celiac Disease Awareness Month, potential of IMU-856

Proactive - Interviews for investors

Immunic Inc chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about new developments in celiac disease research during Celiac Disease Awareness Month. He emphasized the seriousness of the autoimmune condition, noting it is often misdiagnosed due to vague symptoms. “Celiac disease is a really important disease with significant consequences for patients,” Muehler said, citing malnutrition, infertility, and even malignancy risks as complications. The emotional and social toll of the condition, he added, is also substantial, with many patients facing isolation due to dietary restrictions. Muehler discussed Immunic's investigational drug IMU-856, which targets the SIRT-6 protein to regenerate intestinal lining and strengthen gut barrier function. Early results from a Phase 1b trial involving 43 patients indicated improvements across multiple measures: bowel histology, disease symptoms, biomarkers, and micronutrient absorption. At the recent DDW conference, Immunic presented data showing IMU-856's efficacy even in patients with severe intestinal damage. Additionally, the drug's absorption was not hindered by pre-existing gut damage, an encouraging sign for future use. Muehler also noted the drug’s impact on GLP-1 hormone levels, aligning with emerging gastrointestinal treatment trends. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #CeliacDisease #ImmunicInc #IMU856 #AutoimmuneDisorders #GutHealth #BiotechNews #DDW2025 #CeliacTreatment #Epigenetics #GLP1 #MedicalResearch